- Raw materials
- Anticoagulants
- Heparins
- Parnaparin
Filters
Custom request?
Type
Production region
Qualifications
Country of origin
Parnaparin API Manufacturers & Suppliers
3 verified results
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Commercial-scale Suppliers
All certificates
All certificates
All certificates
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Parnaparin | CAS No: 9005-49-6 | GMP-certified suppliers
A medication that prevents and treats venous thromboembolism and manages myocardial infarction by providing anticoagulant effects through low molecular weight heparin properties.
Therapeutic categories
Primary indications
- Used in the prevention and treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism) and in the treatment of myocardial infarction
Product Snapshot
- Parnaparin is a subcutaneous injectable anticoagulant formulation
- It is primarily indicated for prevention and treatment of venous thromboembolism and management of myocardial infarction
- The product holds both approved and investigational status in key regulatory markets
Clinical Overview
As a glycosaminoglycan, parnaparin exerts its anticoagulant effect through the inhibition of activated coagulation factors, although specific pharmacodynamic parameters and detailed mechanisms of action are not fully detailed in available data. Generally, LMWHs like parnaparin enhance the activity of antithrombin III, leading to the inhibition of factor Xa and, to a lesser extent, factor IIa (thrombin), thereby interfering with the coagulation cascade.
Pharmacokinetically, low molecular weight heparins typically exhibit predictable absorption profiles following subcutaneous administration, with bioavailability near 90%. Renal excretion is the main elimination pathway, which necessitates cautious dosing in patients with impaired renal function. The half-life and metabolic characteristics of parnaparin align with those commonly associated with LMWHs, supporting once or twice daily dosing regimens in clinical practice.
Safety considerations for parnaparin involve monitoring for bleeding risks, thrombocytopenia, and potential hyperkalemia due to its pharmacological class. Bleeding is the primary adverse effect associated with all anticoagulant therapies, and the risk can increase with concomitant use of other agents affecting hemostasis. Long-term safety data and specific toxicity profiles should be reviewed in the context of the clinical setting.
Parnaparin is approved for clinical use in various regions and may be available under different brand names or generic formulations. When sourcing parnaparin API, quality parameters such as molecular weight distribution, anti-factor Xa activity, sterility, and purity must comply with pharmacopeial standards relevant to low molecular weight heparins. Reliable suppliers should provide comprehensive certification and traceability to ensure compliance with regulatory requirements and to support formulation development and clinical applications.
Identification & chemistry
| Generic name | Parnaparin |
|---|---|
| Molecule type | Small molecule |
| CAS | 9005-49-6 |
| UNII | U6K360XMIU |
| DrugBank ID | DB09260 |
Formulation & handling
- Parnaparin is a small molecule administered via subcutaneous injection, requiring sterile formulation and handling.
- It is sensitive to interaction with anticoagulant/antiplatelet herbs and supplements, necessitating careful consideration of patient concomitant use.
- Formulation must ensure stability in injectable solutions at specified IU/ml strengths without degradation.
Regulatory status
Parnaparin is a type of Heparins
Heparins are a vital subcategory of pharmaceutical Active Pharmaceutical Ingredients (APIs) widely used in the medical industry. These compounds are derived from the mucous membranes of pigs or cows, and they play a crucial role in preventing and treating blood clotting disorders. This technical description will delve into the key aspects of heparins, highlighting their composition, therapeutic applications, and manufacturing process.
Heparins consist of a complex mixture of sulfated polysaccharides, primarily composed of repeating units of glucuronic acid and N-acetylglucosamine. These chains exhibit high molecular weights, ranging from 3,000 to 30,000 Daltons. Their unique chemical structure and anticoagulant properties make them indispensable in the treatment of conditions like deep vein thrombosis, pulmonary embolism, and during cardiac surgeries.
The production of heparins involves a rigorous extraction process from animal tissues, followed by purification and standardization to ensure consistent quality and efficacy. The raw materials undergo several steps, including depolymerization, fractionation, and removal of impurities, resulting in different forms such as unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH). LMWH offers advantages like improved bioavailability, longer half-life, and reduced risk of certain side effects compared to UFH.
Heparins have found widespread usage in various medical settings, including hospitals, clinics, and home-based treatments. As a potent anticoagulant, they effectively prevent clot formation, minimizing the risk of life-threatening conditions. Additionally, heparins also possess anti-inflammatory and immunomodulatory properties, contributing to their therapeutic efficacy in certain diseases beyond anticoagulation.
In summary, heparins are vital pharmaceutical APIs derived from animal tissues, offering unparalleled anticoagulant effects. Their complex composition, diverse therapeutic applications, and stringent manufacturing processes make them indispensable in modern medicine.
Parnaparin (Heparins), classified under Anticoagulants
Anticoagulants are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used to prevent and treat blood clotting disorders. These medications play a crucial role in various medical conditions, including deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation (AF). Anticoagulants work by inhibiting the formation of blood clots or by preventing existing clots from getting larger.
There are different types of anticoagulants available, including direct thrombin inhibitors, vitamin K antagonists, and factor Xa inhibitors. Direct thrombin inhibitors, such as dabigatran, directly target the enzyme thrombin to hinder clot formation. Vitamin K antagonists, like warfarin, interfere with the production of clotting factors that rely on vitamin K. Factor Xa inhibitors, such as rivaroxaban and apixaban, inhibit the activity of factor Xa, a crucial component in the clotting cascade.
Anticoagulants are commonly prescribed to patients at risk of developing blood clots or those with existing clotting disorders. They are often used during surgeries, such as hip or knee replacements, to minimize the risk of post-operative clot formation. Patients with AF, a condition characterized by irregular heart rhythm, may also be prescribed anticoagulants to prevent stroke caused by blood clots.
While anticoagulants offer significant benefits in preventing and treating clot-related conditions, they also carry potential risks, including bleeding complications. Patients taking anticoagulants require careful monitoring to ensure the right dosage is administered, as excessive anticoagulation can lead to hemorrhage. Regular blood tests and close medical supervision are essential to manage the delicate balance between preventing clots and avoiding excessive bleeding.
In conclusion, anticoagulants are a crucial category of pharmaceutical APIs used to prevent and treat blood clotting disorders. They function by inhibiting clot formation or preventing existing clots from enlarging. While highly beneficial, their use requires careful monitoring to minimize the risk of bleeding complications.
Parnaparin API manufacturers & distributors
Compare qualified Parnaparin API suppliers worldwide. We currently have 3 companies offering Parnaparin API, with manufacturing taking place in 3 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| Opocrin S-C Plant | Producer | Italy | Italy | CoA, JDMF | 7 products |
| Syntex | Producer | Argentina | Argentina | CoA, JDMF | 2 products |
| Yantai Dongcheng Bio. | Producer | China | China | CoA, JDMF | 10 products |
When sending a request, specify which Parnaparin API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Parnaparin API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
